Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | ROS1 | P08922 | 3/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | HEXA | P06865 | 1/20 | 0.32 |
| ▸ | HEXB | P07686 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451477 | 0.85 | NTRK1 (0.58) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL14733128 | 0.81 | NTRK1 (0.46) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL12136011 | 0.71 | NTRK1 (0.38) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL774043 | 0.70 | NTRK1 (0.36) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL469136 | 0.70 | NTRK1 (0.36) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL441643 | 0.68 | RHEB (0.40) | — | |
| SCHEMBL439680 | 0.68 | NTRK1 (0.61) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL441181 | 0.68 | NTRK1 (0.35) | NTRK1ACVRL1RETROS1MET | |
| Hydrochloric Acid SCHEMBL3469036 | 0.68 | NTRK1 (0.60) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL12136086 | 0.68 | NTRK1 (0.33) | NTRK1ACVRL1RETROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.